Please use this identifier to cite or link to this item:
Title: European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
Author: Bataller, Alex
Garrido, Ana
Guijarro, Francesca
Oñate, Guadalupe
Diaz Beyá, Marina
Arnan, Montserrat
Tormo, Mar
Vives, Susana
Queipo de Llano, María Paz
Coll, Rosa
Gallardo, David
Vall Llovera, Ferran
Escoda, Lourdes
Garcia Guiñon, Antonio
Salamero, Olga
Sampol, Antonia
Merchan, Brayan M.
Bargay, Joan
Castaño Díez, Sandra
Esteban, Daniel
Oliver Caldés, Aina
Rivero, Andrea
Mozas, Pablo
López Guerra, Mònica
Pratcorona, Marta
Zamora, Lurdes
Costa, Dolors
Rozman, Maria
Nomdedéu Guinot, Josep Francesc
Colomer Pujol, Dolors
Brunet, Salut
Sierra Gil, Jorge
Esteve Reyner, Jordi
Keywords: Leucèmia mieloide
Programes de prevenció
Myeloid leukemia
Prevention programs
Issue Date: 15-Feb-2022
Publisher: American Society of Hematology
Abstract: The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and management of acute myeloid leukemia (AML) have become fundamental guidelines to assess the prognosis and postremission therapy of patients. However, they have been retrospectively validated in few studies with patients included in different treatment protocols. We analyzed 861 patients included in the Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias-12 risk-adapted protocol, which indicates cytarabine-based consolidation for patients allocated to the ELN 2017 favorable-risk group, whereas it recommends allogeneic stem cell transplantation (alloSCT) as a postremission strategy for the ELN 2017 intermediateand adverse-risk groups. We retrospectively classified patients according to the ELN 2017, with 327 (48%), 109 (16%), and 245 (36%) patients allocated to the favorable-, intermediate-, and adverse-risk group, respectively. The 2- and 5-year overall survival (OS) rates were 77% and 70% for favorable-risk patients, 52% and 46% for intermediate-risk patients, and 33% and 23% for adverse-risk patients, respectively. Furthermore, we identified a subgroup of patients within the adverse group (inv(3)/t(3;3), complex karyotype, and/or TP53 mutation/17p abnormality) with a particularly poor outcome, with a 2-year OS of 15%. Our study validates the ELN 2017 risk stratification in a large cohort of patients treated with an ELN-2017 risk-adapted protocol based on alloSCT after remission for nonfavorable ELN subgroups and identifies a genetic subset with a very poor outcome that warrants investigation of novel strategies.
Note: Reproducció del document publicat a:
It is part of: Blood Advances, 2022, vol 6, num 4, p. 1193-1206
Related resource:
ISSN: 2473-9537
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
advancesadv2021005585.pdf1.63 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons